2017/06/28 by Li Yin Drake, Li Y. Drake, Hirohito Kita · 261 citations
Immunology and Microbiology · Medicine · #Acquired immune system #Airway #Biology #Cytokine #Disease #Eosinophilic Esophagitis #IL-33, ST2, and ILC Pathways #Immune system #Immunity #Immunology #Inflammation #Innate immune system #Innate lymphoid cell #Interleukin #Interleukin 33 #Medicine #Pathogenesis #Pathology
paper · doi:10.1111/imr.12552
published in Immunological Reviews 278(1), 173-184 (Wiley)
openalex publication_date 2017/06/28 · openalex created_date 2017/07/14 · openalex updated_date 2026/08/01
Interleukin (IL)-33 is a key cytokine involved in type 2 immunity and allergic airway diseases. Abundantly expressed in lung epithelial cells, IL-33 plays critical roles in both innate and adaptive immune responses in mucosal organs. In innate immunity, IL-33 and group 2 innate lymphoid cells (ILC2s) provide an essential axis for rapid immune responses and tissue homeostasis. In adaptive immunity, IL-33 interacts with dendritic cells, Th2 cells, follicular T cells, and regulatory T cells, where IL-33 influences the development of chronic airway inflammation and tissue remodeling. The clinical findings that both the IL-33 and ILC2 levels are elevated in patients with allergic airway diseases suggest that IL-33 plays an important role in the pathogenesis of these diseases. IL-33 and ILC2 may also serve as biomarkers for disease classification and to monitor the progression of diseases. In this article, we reviewed the current knowledge of the biology of IL-33 and discussed the roles of the IL-33 in regulating airway immune responses and allergic airway diseases.